{"url_path":"/sec/slxn/8-k/2026-07-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","accession_number":"0001178913-26-003551","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-003551-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":324,"has_tables":true,"body_markdown":"false12-31000202241600-0000000NASDAQNASDAQ00020224162026-07-212026-07-210002022416slxn:OrdinarySharesParValue0135PerShareMember2026-07-212026-07-210002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf1552500PerShareMember2026-07-212026-07-21\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\n** **\n\n**Pursuant to Section 13 or 15(d) of the\nSecurities Exchange Act of 1934**\n\n \n\nDate of report (Date of earliest event reported): July 21, 2026 (July 20, 2026)\n\nSilexion Therapeutics Corp\n\n(Exact name of registrant as specified in its charter)\n\nCayman Islands\n\n \n\n**001-42253**\n\n \n\nN/A\n\n(State or other jurisdiction\n\n \n\n(Commission File Number)\n\n \n\n(I.R.S. Employer\n\nof incorporation)\n\n \n\n \n\nIdentification No.)\n\n \n\n**12 Abba Hillel Road**\n\n**Ramat-Gan, Israel**\n\n \n\n**5250606**\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\n**+972-3-756-4999**\n\n(Registrant’s telephone number, including area code)\n\n****\n\n**N/A**\n\n(Former name or former address, if changed since last report)\n\nCheck the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the\nfollowing provisions:\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading Symbol(s)\n\n \n\nName of each exchange on which registered\n\nOrdinary Shares, par value $0.135 per share\n\n \n\nSLXN\n\n \n\nThe Nasdaq Stock Market LLC\n\nWarrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share\n\n \n\nSLXNW\n\n \n\nThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this\nchapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with\nany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}